Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies

Ying Ye, Michael A. McDevitt, Mingzhou Guo, Wei Zhang, Oliver Galm, Steven D. Gore, Judith E. Karp, Jaroslaw P. Maciejewski, Jeanne Kowalski, Hua Ling Tsai, Lukasz P. Gondek, Hsing Chen Tsai, Xiaofei Wang, Craig Hooker, B. Douglas Smith, Hetty E. Carraway, James G. Herman

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis hematologic disorders remain controversial. This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS. In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed. In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (≥RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML. CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation. Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation. These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q-myeloid malignancies.

Original languageEnglish (US)
Pages (from-to)8482-8490
Number of pages9
JournalCancer Research
Volume69
Issue number21
DOIs
StatePublished - Nov 1 2009

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Methylation
Chromatin
Neoplasms
Epigenomics
Leukemia
Histone Code
Chromosomes, Human, Pair 5
Gene Silencing
DNA Methylation
Genes
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. / Ye, Ying; McDevitt, Michael A.; Guo, Mingzhou; Zhang, Wei; Galm, Oliver; Gore, Steven D.; Karp, Judith E.; Maciejewski, Jaroslaw P.; Kowalski, Jeanne; Tsai, Hua Ling; Gondek, Lukasz P.; Tsai, Hsing Chen; Wang, Xiaofei; Hooker, Craig; Smith, B. Douglas; Carraway, Hetty E.; Herman, James G.

In: Cancer Research, Vol. 69, No. 21, 01.11.2009, p. 8482-8490.

Research output: Contribution to journalArticle

Ye, Y, McDevitt, MA, Guo, M, Zhang, W, Galm, O, Gore, SD, Karp, JE, Maciejewski, JP, Kowalski, J, Tsai, HL, Gondek, LP, Tsai, HC, Wang, X, Hooker, C, Smith, BD, Carraway, HE & Herman, JG 2009, 'Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies', Cancer Research, vol. 69, no. 21, pp. 8482-8490. https://doi.org/10.1158/0008-5472.CAN-09-1153
Ye, Ying ; McDevitt, Michael A. ; Guo, Mingzhou ; Zhang, Wei ; Galm, Oliver ; Gore, Steven D. ; Karp, Judith E. ; Maciejewski, Jaroslaw P. ; Kowalski, Jeanne ; Tsai, Hua Ling ; Gondek, Lukasz P. ; Tsai, Hsing Chen ; Wang, Xiaofei ; Hooker, Craig ; Smith, B. Douglas ; Carraway, Hetty E. ; Herman, James G. / Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. In: Cancer Research. 2009 ; Vol. 69, No. 21. pp. 8482-8490.
@article{19f9f1ef9399480eb0890eb3fef3b8af,
title = "Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies",
abstract = "Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis hematologic disorders remain controversial. This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS. In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31{\%}) than those without 5q deletion (14{\%}), whereas no methylation of other 5q genes was observed. In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (≥RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML. CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation. Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation. These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q-myeloid malignancies.",
author = "Ying Ye and McDevitt, {Michael A.} and Mingzhou Guo and Wei Zhang and Oliver Galm and Gore, {Steven D.} and Karp, {Judith E.} and Maciejewski, {Jaroslaw P.} and Jeanne Kowalski and Tsai, {Hua Ling} and Gondek, {Lukasz P.} and Tsai, {Hsing Chen} and Xiaofei Wang and Craig Hooker and Smith, {B. Douglas} and Carraway, {Hetty E.} and Herman, {James G.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-09-1153",
language = "English (US)",
volume = "69",
pages = "8482--8490",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies

AU - Ye, Ying

AU - McDevitt, Michael A.

AU - Guo, Mingzhou

AU - Zhang, Wei

AU - Galm, Oliver

AU - Gore, Steven D.

AU - Karp, Judith E.

AU - Maciejewski, Jaroslaw P.

AU - Kowalski, Jeanne

AU - Tsai, Hua Ling

AU - Gondek, Lukasz P.

AU - Tsai, Hsing Chen

AU - Wang, Xiaofei

AU - Hooker, Craig

AU - Smith, B. Douglas

AU - Carraway, Hetty E.

AU - Herman, James G.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis hematologic disorders remain controversial. This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS. In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed. In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (≥RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML. CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation. Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation. These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q-myeloid malignancies.

AB - Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis hematologic disorders remain controversial. This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS. In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed. In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (≥RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML. CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation. Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation. These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q-myeloid malignancies.

UR - http://www.scopus.com/inward/record.url?scp=70350539558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350539558&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-1153

DO - 10.1158/0008-5472.CAN-09-1153

M3 - Article

C2 - 19826047

AN - SCOPUS:70350539558

VL - 69

SP - 8482

EP - 8490

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -